Navigation Links
A cost-effective way toward personalized cancer drugs
Date:10/25/2013

This news release is available in German.

Before a cancer patient embarks on a course of treatment, tests can be carried out to establish whether or not the chosen cytostatic agent combination is likely to be effective. But the time-consuming and expensive nature of traditional testing methods is prohibiting their widespread use. Collaborating with DITABIS Digital Biomedical Imaging Systems AG and scientists from Universitts-Frauenklinik Tbingen, Fraunhofer researchers have developed a cost-effective, automated system that allows doctors to determine which medications will prove most benefit for each patient. The "DiagnoSYS" system will be on show at BIOTECHNICA 2013 (Booth E09 in Hall 9), which will take place from October 8-10 in Hannover, Germany.

In treating many types of cancer, doctors often use combi-nation of chemotherapy with other treatments. The cytostatic agents used are designed to target faster growing cancer cells. But there is little consistency in how different patients respond to the various treatments: even when dealing with the same type of tumor, there are vast differences in tumor cell reaction to a given treatment. What greatly helps one person may have little effect on another. Thanks to in vitro chemosensitivity testing, it is possible to find the most effective drug for each patient before commencing treatment. The catch is that current methods of testing are extremely expensive and are not covered by standard health insurance plans, meaning that this personalized approach to treating tumors is rarely put into practice.

"Up till now, these tests have mainly been carried out manually," explains biologist Caroline Siegert from the Fraunhofer Institute for Manufacturing Engineering and Automation IPA. Medical laboratory scientists begin by m
'/>"/>

Contact: Axel Storz
axel.storz@ipa.fraunhofer.de
49-711-970-3660
Fraunhofer-Gesellschaft
Source:Eurekalert  

Page: 1 2 3

Related biology news :

1. Researchers develop rapid, cost-effective early detection method for organ transplant injury
2. Cost-effective: Universal HIV testing in India
3. A new cost-effective genome assembly process
4. Cost-effective production of infrared lenses
5. Towards a real understanding of depression
6. Nitrogen fertilizer remains in soils and leaks towards groundwater for decades, researchers find
7. Toward understanding the dangers of the fake marijuana called Spice or K2
8. Insect-inspired super rubber moves toward practical uses in medicine
9. Toward a safer form of acetaminophen
10. New materials, progress toward an HIV vaccine, and more at meeting of crystallographers
11. UCLA stem cell gene therapy for sickle cell disease advances toward clinical trials
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
A cost-effective way toward personalized cancer drugs
(Date:7/28/2014)... 28, 2014)The Brain & Behavior Research Foundation today ... Freedman Prizes, recognizing exceptional clinical and basic research ... NARSAD Young Investigator Grants. The grants enable early ... and psychosocial research for the prevention, early detection, ... one in four people. , Six young scientistswinners ...
(Date:7/28/2014)... Inspired Engineering at Harvard University today announced that ... a newly formed private company to accelerate development ... The announcement follows a worldwide license ... and the start-up Emulate Inc., relating to the ... , "This is a big win towards ...
(Date:7/27/2014)... one of the largest prevalence studies to date, researchers ... prevalence estimates for the hepatitis C virus (HCV). Findings ... for the Study of Liver Diseases, indicate that genotype ... million patients infected of which one-third reside in East ... is the next most prevalent, followed by genotypes 2, ...
Breaking Biology News(10 mins):The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 2The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 3The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 4Wyss Institute's technology translation engine launches 'Organs-on-Chips' company 2Wyss Institute's technology translation engine launches 'Organs-on-Chips' company 3Hepatitis C virus genotype 1 is most prevalent worldwide 2
... Ind. - As the United Nations climate negotiations proceed ... toward quantifying the "socioclimatic" exposure of different countries to ... University and the Abdus Salam International Centre for Theoretical ... the United States - major greenhouse gas-emitting nations that ...
... $50 billion in manufactured goods last year, according to ... $2.6 trillion. By 2011, over $15 billion in nano-enabled ... $3 billion in 2006. And industry experts project that ... consumer food products by 2010. Yet, ...
... from the Early Jurassic has been discovered in Antarctica. ... hammeri and lived about 190 million years ago. , ... based on partial foot, leg and ankle bones found ... at an elevation of more than 13,000 feet. , ...
Cached Biology News:Scientists develop new measure of 'socioclimactic' risk 2Scientists develop new measure of 'socioclimactic' risk 3Scientists develop new measure of 'socioclimactic' risk 4FDLI, PEN co-sponsor major conference on nanotechnology 2FDLI, PEN co-sponsor major conference on nanotechnology 3Massive dinosaur discovered in Antarctica sheds light on life, distribution of sauropodomorphs 2
(Date:7/28/2014)... 2014 According to ... (Consumables, Instruments, Services), Methods (Phenotypic, Genotypic), Applications (Pharmaceutical, Diagnostic, ... Characterization) - Global Forecasts to 2019" published ... estimated at $896.5 Million in 2014 and ... 2019, growing at a CAGR of 5.9% ...
(Date:7/28/2014)... , July 28, 2014   Propeller Health , ... announced the hire of Brad Towle as ... be responsible for driving the company,s sales growth, customer ... in healthcare, and specifically his past role in the ... the company at this pivotal time in the industry," ...
(Date:7/28/2014)... The global market for biotechnology is expected ... a new study by Grand View Research, Inc. Increasing ... vaccines and drugs in an attempt to improve healthcare ... to drive market demand over the next six years. ... the use of genetically engineered seeds is expected to ...
(Date:7/28/2014)... Research and Markets has announced the ... report to their offering. ... technique used to determine the size of a particle in ... to analyze the size of particles as it can affect ... performed to determine the behavior and nature of a material, ...
Breaking Biology Technology:Microbial Identification Market worth $1,194.1 Million by 2019 2Microbial Identification Market worth $1,194.1 Million by 2019 3Propeller Health Hires Brad Towle as Senior Vice President of Business and Client Development 2Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 2Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 3Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 4Global Particle Size Analysis Market 2014-2018 2
... , , ... Tobira Therapeutics Inc., a clinical stage biotechnology company committed ... life-threatening and life-altering infectious diseases, today announced pharmacokinetic data ... of TBR-652 in sixty healthy volunteers. TBR-652, a ...
... CAMBRIDGE, Mass., Sept. 14 Ironwood Pharmaceuticals, Inc. today ... officer and senior vice president of marketing and sales. Mr. McCourt ... lead Ironwood,s growing marketing and sales team. , , ... , Mr. McCourt comes to Ironwood from Amgen, where ...
... , , , JOHNSON CITY, ... Rx100, a potent radioprotectant as well as radiomitigator, protects against lethal, ... after exposure. , , In recent experiments, ... subcutaneous dose at either 48 or 72 hours after lethal, whole-body ...
Cached Biology Technology:Tobira Therapeutics Inc. Announces Phase I Pharmacokinetic Data of TBR-652 for the Treatment of HIV 2Ironwood Appoints Thomas McCourt As Chief Commercial Officer and Senior Vice President of Marketing and Sales 2Rx100 Rescues Life if Administered Up to 72 Hours After Exposure to Lethal, Whole-Body Radiation! 2
2'-Fluorine-CTP (2'-F-CTP) is readily incorporated into transcripts by T7 and SP6 R&DNA™ Polymerase and is available separately....
... J. Karn (1995) This volume ... and methods for the study of major ... reverse transcriptase, ribonuclease H, integrase and protease. ... binding assays; Tat and Rev assays; HIV/CD4 ...
Human Glypican 2 Biotinylated Affinity Purified PAb...
Human Contactin-2/TAG1 Affinity Purified Polyclonal Ab...
Biology Products: